<DOC>
<DOCNO>EP-0625214</DOCNO> 
<TEXT>
<INVENTION-TITLE>
CMV PROBES FOR USE IN SOLUTION PHASE SANDWICH HYBRIDIZATION ASSAYS.
</INVENTION-TITLE>
<CLASSIFICATIONS>C07H2100	C07H2104	C12N1509	C12N1509	C12Q168	C12Q168	C12Q170	C12Q170	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07H	C07H	C12N	C12N	C12Q	C12Q	C12Q	C12Q	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07H21	C07H21	C12N15	C12N15	C12Q1	C12Q1	C12Q1	C12Q1	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Novel DNA probe sequences for detection of CMV in a sample in a solution phase sandwich hybridization assay are described. Amplified nucleic acid hybridization assays using the probes are exemplified.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
CHIRON CORP
</APPLICANT-NAME>
<APPLICANT-NAME>
CHIRON CORPORATION
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
KOLBERG JANICE A
</INVENTOR-NAME>
<INVENTOR-NAME>
SHEN LU-PING
</INVENTOR-NAME>
<INVENTOR-NAME>
URDEA MICHAEL S
</INVENTOR-NAME>
<INVENTOR-NAME>
KOLBERG, JANICE, A.
</INVENTOR-NAME>
<INVENTOR-NAME>
SHEN, LU-PING
</INVENTOR-NAME>
<INVENTOR-NAME>
URDEA, MICHAEL, S.
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
 CMV PROBES FOR USE IN SOLUTION PHASESANDWICH HYBRIDIZATION ASSAYSDESCRIPTIONTechnical FieldThis invention is in the field of nucleic acid hybridization assays. More specifically, it relates to novel nucleic acid probes for detecting Cytomegalovirus (CMV) .Background ArtCytomegalovirus (CMV) is a member of the herpes virus family, causing clinical illness of particular importance in neonates, immunocompromised, and immunosuppressed patients.Chou and Dennison (J.Infect. Pis. 163:1229- 1234, 1991) disclose the nucleotide sequence of part of the envelope glycoprotein B gene of human CMV that encodes epitopes recognized by virus-neutralizing monoclonal antibodies for 12 distinct clinical isolates of CMV.U.S. No. 4,731,325, filed 24 January, 1985, discloses restriction fragments of CMV DNA in sandwich hybridizations assays. U.S. No. 4,762,780, filed 5 January, 1987, discloses the use of restriction fragments of CMV DNA which do not cross-hybridize with human DNA for use in hybridization assays for CMV. 

 EPA 0271201, filed 2 November 1987, discloses the use of cloned restriction fragments of CMV DNA for use in hybridization assays for CMV.PCT WO 91/02091, filed 9 August 1990, discloses probe sequences to detect and distinguish herpesviruses, including a 31 residue oligonucleotide probe sequence for CMV detection.Spector et al. (Clin. Chem. 35/8:1581- 1587,1989) disclose a 32P-labeled RNA probe and three single-stranded DNA oligomer capture probes complementary to mRNA encoding the CMV late matrix protein for use in a "target cycling" assay, and four 20-oligonucleotide primers and two 40-oligonucleotide probes for PCR amplification of CMV. Commonly owned U.S. 4,868,105 describes a solution phase nucleic acid sandwich hybridization assay in which analyte nucleic acid is first hybridized in solution to a labeling probe set and to a capturing probe set in a first vessel. The probe-analyte complex is then transferred to a second vessel that contains a solid- phase-immobilized probe that is substantially complementary to a segment of the capturing probes. The segments hybridize to the immobilized probe, thus removing the complex from solution. Having the analyte in the form of an immobilized complex facilitates subsequent separation steps in the assay. Ultimately, single stranded segments of the labeling probe set are hybridized to labeled probes, thus permitting the analyte-containing complex to be detected via a signal generated directly or indirectly from the label.Commonly owned European Patent Application
</DESCRIPTION>
<CLAIMS>
Claims 1. A synthetic oligonucleotide useful as an amplifier probe in a sandwich hybridization assay for CMV comprising a first segment comprising a nucleotide sequence substantially complementary to a segment of CMV nucleic acid; and a second segment comprising a nucleotide sequence substantially complementary to an oligonucleotide multimer, wherein the CMV nucleic acid segment is selected from the group consisting of
CCG TTGATGTARCYGCGCAACGTRTCRTAGGT (SEQ ID NO:6), CACACACCARGCYTCKGCGATYTGYGYYARCGC (SEQ ID NO:7), TTCCYTGAAGACCTCYAGGGWGCGCCGTTGATC (SEQ ID NO:8), YGAGAGAATRGCTGAYGGRTTGATCTTGCTRAG (SEQ ID NO:9) , GAAACGCGCGGC-AATCGGTTTGTTGTARATGGC (SEQ ID NO:10), CΑCGC-AGCTGGCl-^^RCCαi RACATCACCCAT (SEQ ID NO:11) , ACGCΑGC-ACC TRACGCTKGTTTGG'I-TRATRGT (SEQ ID NO:12), GCAGCGTCCTGGCGAYTCYTTCACRTTCATATC (SEQ ID NO:13), GRCGAAATTAAAGATGACCACKGGTCGYGAGTA (SEQ ID NO:14), RCCCAG TGACCGTACTGCACRTACGAGCTGTT (SEQ ID NO:15), GCGGTGG TGCCCAACAGGATTTCGTTRTCCTC (SEQ ID NO:16), GATCTTGAGGCTGGGAARCTGACATTCCTCAGT (SEQ ID NO:17), CACGTACTCGTAGGCCGAGTTSCCGGCGATGAA (SEQ ID NO:18) , GCTGAGGTC-aATCATGCGTTTGAAGAGGTAGTC (SEQ ID NO:19), YARGGCGATCATGCTGTCGACDGTRGAGATRCT (SEQ ID NO:20) , CCπΩAAGTCRGTRTTTTCCAGCGGGTCGATRTC (SEQ ID NO:21), CACATATΓCATAGGCCGAGTΓSCCGGCGATGAA (SEQ ID NO:22) , CGCCACCGGCGAGATGCCGCATAGGCGACGGAG (SEQ ID NO:23), GCATGTCGTCCCTTCGACGTACACTTCCTGACG (SEQ ID NO:24) , CGGGATGATGGTCAGCTCCTCGTAGCATTGGGC (SEQ ID NO:25) , C GCAGCCGCTTGTTCARCGAGCGGCCCTGATT (SEQ ID NO:26) , ACGGΕ-røACCGCTATATGGTTGCACAGCΑAGCC (SEQ ID NO:27) , CGTCTGGATATTCACATCGGACTGGCTTGACGG (SEQ ID NO:28) , 


 GCGCGTTGTCAGGTCCAGCAGGTCCTGCTCCAC (SEQ ID NO:29) ,
GAGGGCCGAAAGGACTCCAGCCAAGTGGGGGAT (SEQ ID NO:30),
GTGGTAGGCCGATGAAGAAGAGAATAGGCTTTT (SEQ ID NO:31),
CCTCAGCGCCTCCTCCGCCTCCTGGATGTAGCT (SEQ ID NO:32), TCGTTCCGGTATATCCGTAAACAGGTTGTACTC (SEQ ID NO:33) ,
GGACCAGTAGGTAAAATCCGACAAGGAATATAT (SEQ ID NO:34),
GCCCACCCGCTTGACGATAACCTCCGAGGTACG (SEQ ID NO:35) ,
CTGGTGATAC-ACΑTTTAGCTGCTGGATGGTGAT (SEQ ID NO:36) ,
GCGACTGATGCCGTTCATGAGCGCCCGGCACAG (SEQ ID NO:37) , GAAGATGTCCTCCACGTCCTCCCCGTACAGATG (SEQ ID NO:38) ,
CTCCTCCCCGTCCAACGCCTTTTCCCCGAGCAC (SEQ ID NO:39) ,
GGGGGCGGCAAAGACCGACCCCACGAACATGCG (SEQ ID NO:40) .
2. The synthetic oligonucleotide of claim 1, wherein said second segment comprises
AGGCATAGGACCCGTGTCTT (SEQ ID NO:51).
3. A synthetic oligonucleotide useful as a capture probe in a sandwich hybridization assay for CMV comprising a first segment comprising a nucleotide sequence substantially complementary to a segment of CMV nucleic acid; and a second segment comprising a nucleotide sequence substantially complementary to an oligonucleotide bound to a solid phase, wherein said CMV nucleic acid segment is selected from the group consisting of
ACGC--ARYTC-TTTCTGCGAGTAAAGTTCC-AGTAC (SEQ ID NO:41) ,
CΑTGATCTCYTCGAGRTC-AAAAACGTTGCTGGA (SEQ ID NO:42) ,
CTTTACCCGCTGCTTGTACGAGTTGAAYTCGCG (SEQ ID NO:43) ,
•
 CGGYARCGGGTCGACTACCTTGTCCTCCACGTA (SEQ ID NO:44) , GCTCATGAGGTCGTCCAGACCCTTGAGGTAGGG (SEQ ID NO:45) , 


 CTTTACCCGCTGCTTATACGAATTGAAYTCGCG (SEQ ID NO: 6) , GCTGAGGGATGTGATGAGGTCGATGATCCTGTT (SEQ ID NO:47) , GTTGAACACCGGGTTGTCCTCGAAAGCTTGAAT (SEQ ID NO:48) , TTTGGTGTA(---ATCTCGTTGCTTTCGTGGAGCTT (SEQ ID NO:49) , CGGACGTCGAATCTCCTCGAGAATATGCTTGAT (SEQ ID NO:50) .
4. The synthetic oligonucleotide of claim 3, wherein said second segment comprises
CTTCTTTGGAGAAAGTGGTG (SEQ ID NO:53) .
5. A set of synthetic oligonucleotides useful as amplifier probes in a sandwich hybridization assay for CMV, coiπprising two oligonucleotides, wherein each member of the set comprises a first segment comprising a nucleotide sequence substantially complementary to a segment of CMV nucleic acid; and a second segment comprising a nucleotide sequence substantially complementary to an oligonucleotide multimer, wherein the CMV nucleic acid segments are
CCGRTTGATGTARCYGCGCAACGTRTCRTAGGT (SEQ ID NO:6), CACACACCARGCYTCKGCGATYTGYGYYARCGC (SEQ ID NO:7), TTCCYTGAAGACCTCYAGGGWGCGCCGTTGATC (SEQ ID NO:8), YGAGAGAATRGCTGAYGGRTTGATCTTGCTRAG (SEQ ID NO:9) , GAAACGCGCGGCLΑATCGGTTTGTTGTARATGGC (SEQ ID NO:10), CΑCGC-AGCTGGCCaRRCCC--ARRAC-ΑTCACCCAT (SEQ ID NO:11) , ACGC--AGC-ACCTTRACGCTKGTTTGGTTRATRGT (SEQ ID NO:12) , GCAGCGTCCTGGCGAYTCYTTCACRTTCATATC (SEQ ID NO:13) , GRCGAAATTAAAGATGACCACKGGTCGYGAGTA (SEQ ID NO:14), RCCC--AGTTGACCGTACTGCACRTACGAGCTGTT (SEQ ID NO:15) , GCGGTGGTTGCCCAACAGGATTTCGTTRTCCTC (SEQ ID NO:16) , 


 GATCTTGAGGCTGGGAARCTGACATTCCTCAGT (SEQ ID NO:17 CACGTACTCGTAGGCCGAGTTSCCGGCGATGAA (SEQ ID NO:18 GCTGAGGTC-.AATCATGCGTTTGAAGAGGTAGTC (SEQ ID NO:19 YARGGCGATCATGCTGTCGACDGTRGAGATRCT (SEQ ID NO:20 CCTGAAGTCRGTRTTTTCCAGCGGGTCGATRTC (SEQ ID NO:21 CACATATTCATAGGCCGAGTTSCCGGCGATGAA (SEQ ID NO:22 CGCCACCGGCGAGATGCCGCATAGGCGACGGAG (SEQ ID NO:23 GCATGTCGTCCCTTCGACGTACACTTCCTGACG (SEQ ID NO:24 CGGGATGATGGTCAGCTCCTCGTAGCATTGGGC (SEQ ID NO:25 CTGCAGCCGCTTGTTCARCGAGCGGCCCTGATT (SEQ ID NO:26 ACGGTGGACCGCTATATGGTTGCACAGCAAGCC (SEQ ID NO:27 CGTCTGGATATTCACATCGGACTGGCTTGACGG (SEQ ID NO:28 GCGCGTTGTC-AGGTCCAGCAGGTCCTGCTCCAC (SEQ ID NO:29 GAGGGCCGAAAGGACTCCAGCCAAGTGGGGGAT (SEQ ID NO:30 GTGGTAGGCCGATGAAGAAGAGAATAGGCTTTT (SfiQ ID NO:31 CCTCAGCGCCTCCTCCGCCTCCTGGATGTAGCT (SEQ ID NO:32 TCGTTCCGGTATATCCGTAAACAGGTTGTACTC (SEQ ID NO:33 GGACCAGTAGGTAAAATCCGACAAGGAATATAT (SEQ ID NO:34 GCCCACCCGCTTGACGATAACCTCCGAGGTACG (SEQ ID NO:35 CTGGTGATACACATTTAGCTGCTGGATGGTGAT (SEQ ID NO:36 GCGACTGATGCCGTTCATGAGCGCCCGGCACAG (SEQ ID NO:37 GAAGATGTCCTCCACGTCCTCCCCGTACAGATG (SEQ ID NO:38 CTCCTCCCCGTCC^CGCCTTTTCCCCGAGCAC (SEQ ID NO:39 GGGGGCGGCAAAGACCGACCCCACGAACATGCG (SEQ ID NO:40
6. The set of synthetic oligonucleotides of claim 5, wherein said second segment comprises
AGGCATAGGACCCGTGTCTT (SEQ ID NO:51) .
7. A set of synthetic oligonucleotides useful as capture probes in a sandwich hybridization assay for CMV, comprising two oligonucleotides, wherein each member of the set comprises 


 a first segment comprising a nucleotide sequence substantially complementary to a segment of CMV nucleic acid; and a second segment comprising a nucleotide sequence substantially complementary to an oligonucleotide bound to a solid phase, wherein said CMV nucleic acid segments are
ACGC^YTCTTTCTGCGAGTAAAGTTCCAGTAC (SEQ ID NO:41) , CATGATCTCYTCGAGRTCAAAAACGTTGCTGGA (SEQ ID NO:42) , CTTTACCCGCTGCTTGTACGAGTTGAAYTCGCG (SEQ ID NO:43) , CGGY-^CGGGTCGACTACCTTGTCCTCC-ACGTA (SEQ ID NO:44) , GCTCATGAGGTCGTCCAGACCCTTGAGGTAGGG (SEQ ID NO:45) , CTTTACCCGCTGCTTATACGAATTGAAYTCGCG (SEQ ID NO: 6) , GCTGAGGGATGTGATGAGGTCGATGATCCTGTT (SEQ ID NO:47) , GTTGAACACCGGGTTGTCCTCGAAAGCTTGAAT (SEQ ID NO:48) , TTTGGTGTAC^TCTCGTTGCTTTCGTGGAGCTT (SEQ ID NO:49) , CGGACGTCGAATCTCCTCGAGAATATGCTTGAT (SEQ ID NO:50) .
8. The set of synthetic oligonucleotides of claim 7, wherein said second segment comprises
CTTCTTTGGAGAAAGTGGTG (SEQ ID NO:53) .
9. A solution sandwich hybridization assay for detecting the presence of CMV in a sample, comprising (a) contacting the sample under hybridizing conditions with an excess of (i) amplifier probes comprising the set of synthetic oligonucleotides of claim 5 and (ii) a set of capture probe oligonucleotides wherein the capture probe oligonucleotide comprises a first segment comprising a nucleotide sequence that is substantially complementary to a segment of CMV nucleic acid and a second segment that is substantially 


 complementary to an oligonucleotide bound to a solid phase;
(b) contacting the product of step (a) under hybridizing conditions with said oligonucleotide bound to the solid phase;
(c) thereafter separating materials not bound to the solid phase;
(d) contacting the bound product of step (c) under hybridization conditions with the nucleic acid multimer, said multimer comprising at least one oligonucleotide unit that is substantially complementary to the second segment of the amplifier probe polynucleotide and a multiplicity of second oligonucleotide units that are substantially complementary to a labeled oligonucleotide;
(e) removing unbound multimer;
(f) contacting under hybridizing conditions the solid phase complex product of step (e) with the labeled oligonucleotide; (g) removing unbound labeled oligonucleotide; and
(h) detecting the presence of label in the solid phase complex product of step (g) .
10. A solution sandwich hybridization assay for detecting the presence of CMV in a sample, comprising
(a) contacting the sample under hybridizing conditions with an excess of (i) a set of amplifier probe oligonucleotides wherein the amplifier probe oligonucleotide comprises a first segment comprising a nucleotide sequence substantially complementary to a segment of CMV nucleic acid and a second segment comprising a nucleotide sequence substantially complementary to an oligonucleotide unit of a nucleic 


 acid multimer and (ii) capture probes comprising the set of synthetic oligonucleotides of claim 7;
(b) contacting the product of step (a) under hybridizing conditions with said oligonucleotide bound to the solid phase;
(c) thereafter separating materials not bound to the solid phase;
(d) contacting the bound product of step (c) under hybridization conditions with the nucleic acid multimer, said multimer comprising at least one oligonucleotide unit that is substantially complementary to the second segment of the amplifier probe polynucleotide and a multiplicity of second oligonucleotide units that are substantially complementary to a labeled oligonucleotide;
(e) removing unbound multimer;
(f) contacting under hybridizing conditions the solid phase complex product of step (e) with the labeled oligonucleotide; (g) removing unbound labeled oligonucleotide; and
(h) detecting the presence of label in the solid phase complex product of step (g) .
11. A kit for the detection of CMV in a sample comprising in combination
(i) a set of amplifier probe oligonucleotides wherein the amplifier probe oligonucleotide comprises a first segment comprising a nucleotide sequence substantially complementary to a segment of CMV nucleic acid and a second segment comprising a nucleotide sequence substantially complementary to an oligonucleotide unit of a nucleic acid multimer;
(ii) a set of capture probe oligonucleotides wherein the capture probe oligonucleotide comprises a 


first segment comprising a nucleotide sequence that is substantially complementary to a segment of CMV nucleic acid and a second segment that is substantially complementary to an oligonucleotide bound to a solid phase;
(iii) a nucleic acid multimer, said multimer comprising at least one oligonucleotide unit that is substantially complementary to the second segment of the amplifier probe polynucleotide and a multiplicity of second oligonucleotide units that are substantially complementary to a labeled oligonucleotide; and
(iv) a labeled oligonucleotide.
12. The kit of claim 11, wherein said set of said amplifier probe oligonucleotides is the set of claim
5.
13. The kit of claim 11, wherein said set of said capture probe oligonucleotides is the set of claim 7. 14. The kit of claim 11, said kit further comprising instructions for the use thereof. 

</CLAIMS>
</TEXT>
</DOC>
